About dry eye syndrome
Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.
Technavio's analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global dry eye syndrome market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of teardrops and anti-inflammatory drugs used in the treatment of dry eye syndrome.
Technavio's report, Global Dry Eye Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Alcon
• Allergan
• Otsuka Holdings
• Santen Pharmaceuticals
Other prominent vendors
• Acadia Pharmaceuticals
• Aciex
• Allostera Pharma
• arGentis
• Auven Therapeutics (Celtic)
• Bridge Pharma
• Can-Fite
• Cellzome
Key market driver
• Growing prevalence of dry eye syndrome
• For a full, detailed list, view our report
Key market challenge
• Self-medication by patients
• For a full, detailed list, view our report
Key market trend
• Growing awareness about the syndrome
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding dry eye syndrome
Types of dry eye syndrome
Risk factors for dry eye syndrome
Signs and symptoms
Causes of dry eye syndrome
Epidemiology
Diagnosis
Disease management
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline analysis
Cyclokat
Diquas
EBI-005
MIM-D3
Lifitegrast
RGN-259
EBI-005
EGP-437
PART 08: Market segmentation by sub-type of dry eye
PART 09: Market segmentation by drug type
Oral antibiotics
Eye drops
Eye inserts
Eye ointments
PART 10: Geographical segmentation
Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
Alcon
Allergan
Otsuka Holdings
Santen Pharmaceuticals
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List Of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Regional prevalence of dry eye syndrome
Exhibit 03: Diagnosis of dry eye syndrome
Exhibit 04: Surgical options
Exhibit 05: Punctal plugs
Exhibit 06: Global dry eye syndrome market 2014-2019 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by sub-type of dry eye
Exhibit 09: Dry eye syndrome: pharmacologic therapy
Exhibit 10: Artificial tears: Different generations
Exhibit 11: Global dry eye syndrome market share 2014
Exhibit 12: Global dry eye syndrome: Key drivers
Exhibit 13: Impact of drivers
Exhibit 14: Global dry eye syndrome: Key challenges
Exhibit 15: Impact of drivers and challenges
Exhibit 16: Global dry eye syndrome: Emerging trends
Exhibit 17: Global dry eye syndrome market share analysis 2014
Exhibit 18: Alcon: Business strategy
Exhibit 19: Alcon: Distribution of sales by category 2014
Exhibit 20: Alcon: Region-wise sales distribution 2014 ($ millions)
Exhibit 21: Alcon: Region-wise sales distribution 2013 ($ millions)
Exhibit 22: Systane: Global sales 2011-2014 ($ millions)
Exhibit 23: Allergan: Business strategy
Exhibit 24: Eye care pharmaceuticals: Global sales 2011-2014 ($ millions)
Exhibit 25: Restasis: Global sales 2011-2014 ($ millions)
Exhibit 26: Santen Pharmaceuticals: Business strategy
Exhibit 27: Hyalein: Global sales 2011-2014 ($ millions)
Exhibit 28: Diquas: Global sales 2011-2014 ($ millions)
Exhibit 29: Prescription ophthalmics : Global sales 2011-2014 ($ millions)
Exhibit 30: Alcon: Business segmentation 2014
Exhibit 31: Allergan: Business segmentation by revenue 2014
Exhibit 32: Allergan: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 33: Allergan: Geographical segmentation by revenue 2014
Exhibit 34: Santen Pharmaceutical: Business/Product segmentation 2014 by revenue
